Given that CR-1 is often expressed at high levels in NSCLC [55, 56], it is possible that the anti-GPC1 mAb treatment hinders the interaction between CR-1 and its cognate receptors, thereby alleviating the need for recruiting the phosphorylated Src in cytoplasm. The gene discussed is GPC1; the disease is non-small cell lung carcinoma.